July 11, 2023
Merck & Co. on Tuesday likened the Inflation Reduction Act's new system of drug-price negotiations to an oppressive political regime and derided the Biden administration's rush for legal cover amid a cloudburst of litigation as "highly dubious" and "constitutionally irrelevant."
June 16, 2023
Bristol-Myers Squibb Co. on Friday lobbed yet another challenge to landmark legislation allowing Medicare to negotiate drug prices, slamming the law as unconstitutional and not actually involving negotiations "in any ordinary sense of the word," according to a suit filed in New Jersey federal court.